Roivant Sciences Ltd [NASDAQ: ROIV] price plunged by -2.12 percent to reach at -$0.23.
The one-year ROIV stock forecast points to a potential upside of 37.53. The average equity rating for ROIV stock is currently 1.17, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Roivant Sciences Ltd [ROIV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ROIV shares is $17.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ROIV stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Roivant Sciences Ltd shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 15, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on January 05, 2024, representing the official price target for Roivant Sciences Ltd stock. Previously, the target price had yet another raise to $14, while Deutsche Bank analysts kept a Buy rating on ROIV stock.
The Average True Range (ATR) for Roivant Sciences Ltd is set at 0.29, with the Price to Sales ratio for ROIV stock in the period of the last 12 months amounting to 62.90. The Price to Book ratio for the last quarter was 1.44, with the Price to Cash per share for the same quarter was set at 8.85.
ROIV Stock Performance Analysis:
Roivant Sciences Ltd [ROIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.12. With this latest performance, ROIV shares gained by 0.57% in over the last four-week period, additionally plugging by 6.20% over the last 6 months – not to mention a drop of -10.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ROIV stock in for the last two-week period is set at 42.70, with the RSI for the last a single of trading hit 38.76, and the three-weeks RSI is set at 45.00 for Roivant Sciences Ltd [ROIV]. The present Moving Average for the last 50 days of trading for this stock 10.84, while it was recorded at 10.72 for the last single week of trading, and 10.55 for the last 200 days.
Insight into Roivant Sciences Ltd Fundamentals:
Roivant Sciences Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 25.10 and a Current Ratio set at 25.24.
Roivant Sciences Ltd [ROIV] Institutonal Ownership Details
The top three institutional holders of ROIV stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in ROIV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in ROIV stock with ownership which is approximately 5.1238%.
